Elanco Animal Health Incorporated (ELAN) |
|
20.62 0.99 (5.04%)
|
07-02 20:20 |
|
Open: |
19.6 |
Pre. Close: |
19.63 |
|
High:
|
20.655 |
Low:
|
19.545 |
|
Volume:
|
6,338,400 |
Market Cap:
|
9,776(M) |
|
|
|
|
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.7 - 20.84 |
20.84 - 20.96 |
|
Low:
|
19.22 - 19.39 |
19.39 - 19.54 |
|
Close:
|
20.35 - 20.63 |
20.63 - 20.88 |
|
Technical analysis |
as of: 2022-07-01 4:21:34 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 26.62 One year: 29.11 |
| Support: |
Support1: 19.34 Support2: 16.09 |
| Resistance: |
Resistance1: 22.79 Resistance2: 24.93 |
| Pivot: |
20.42  |
| Moving Average: |
MA(5): 20.17 MA(20): 21.22
MA(100): 24.67 MA(250): 28.57 |
| MACD: |
MACD(12,26): -1 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 22.6 %D(3): 14.8 |
| RSI: |
RSI(14): 42.2 |
| 52-week: |
High: 37.49 Low: 19.34 |
| Average Vol(K): |
3-Month: 4,730 (K) 10-Days: 5,708 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELAN ] has closed below upper band by 39.8%. Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sat, 02 Jul 2022
IFM Investors Pty Ltd Buys 8624 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Fri, 01 Jul 2022
Elan Cup 2022 to take place in Venice on the 23rd of July - Sail World
Thu, 30 Jun 2022
Jonathan Majors Signs With WME - Deadline
Thu, 30 Jun 2022
Professional Winter Sports Equipment Market is Booming Worldwide with Amer Sports, ELAN, DOO – Designer Women - Designer Women
Thu, 30 Jun 2022
Industrial Ceramics Market 2022 Competitive Insights – Kyocera, CM Cera, Anderman Ceramics, Elan Technology – Designer Women - Designer Women
Mon, 27 Jun 2022
Elan to Restart Production of Bicycles - Total Slovenia News
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
473 (M) |
| Shares Float |
425 (M) |
|
% Held by Insiders
|
4.1 (%) |
|
% Held by Institutions
|
105.6 (%) |
|
Shares Short
|
16,130 (K) |
|
Shares Short P.Month
|
14,380 (K) |
Stock Financials |
|
EPS
|
-1.43 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
16.23 |
|
Profit Margin (%)
|
-10 |
|
Operating Margin (%)
|
7.8 |
|
Return on Assets (ttm)
|
1.3 |
|
Return on Equity (ttm)
|
-5.9 |
|
Qtrly Rev. Growth
|
-2.3 |
|
Gross Profit (p.s.)
|
5.68 |
|
Sales Per Share
|
10.08 |
|
EBITDA (p.s.)
|
2.19 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
483 (M) |
|
Levered Free Cash Flow
|
785 (M) |
Stock Valuations |
|
PE Ratio
|
-14.42 |
|
PEG Ratio
|
1.3 |
|
Price to Book value
|
1.26 |
|
Price to Sales
|
2.04 |
|
Price to Cash Flow
|
20.19 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
